Abstract: OBJECTIVE To investigate the influence of flupentixol and melitracen tablets in residual diziness of gerontal patients with secondary benign paroxysmal positional vertigo (BPPV). METHODS The clinical data of 84 gerontal patients (age >65) with secondary BPPV who received treatment in the neurology clinic of the First Hospital of Jiaxing were collected. These patients were divided into two groups:Flupentixol and melitracen tablets group (n=42) and conventional treatment group (n=42). The duration of residual diziness and the score of Dizziness Handicap Inventory (DHI) were analyzed before treatment, three days, one week and two weeks after treatment. RESULTS The duration of residual diziness in flupentixol and melitracen tablets group was shorter than conventional treatment group (P=0.002). Compared with conventional treatment group after resetting success, the score of flupentixol and melitracen tablets group significantly decreased for one week and two week after treatment (P=0.040 and P=0.030, respectively). CONCLUSION flupentixol and melitracen tablets group have shorter duration of residual diziness, lower score of DHI of one week or two weeks after treatment.